Cargando…

Anti-interleukin-1 agents for pericarditis: a primer for cardiologists( )

Anti-interleukin (IL)-1 agents have been developed for the treatment of autoinflammatory and rheumatic conditions, where overproduction of IL-1 is an important pathophysiologic process. IL-1α and IL-1β are the most studied members of the IL-1 family of cytokines and have the strongest proinflammator...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imazio, Massimo, Lazaros, George, Gattorno, Marco, LeWinter, Martin, Abbate, Antonio, Brucato, Antonio, Klein, Allan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	State of the Art Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375710/ https://www.ncbi.nlm.nih.gov/pubmed/34528670 http://dx.doi.org/10.1093/eurheartj/ehab452

Ejemplares similares

Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis
por: Brucato, Antonio, et al.
Publicado: (2023)

Recurrent pericarditis: an update on diagnosis and management
por: Andreis, Alessandro, et al.
Publicado: (2021)

AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management
por: Witteles, Ronald M., et al.
Publicado: (2019)

Interleukin‐1 Trap Rilonacept Improved Health‐Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY
por: Brucato, Antonio, et al.
Publicado: (2022)

Colchicine and the heart
por: Imazio, Massimo, et al.
Publicado: (2021)

Emerging Therapies for Recurrent Pericarditis: Interleukin‐1 inhibitors
por: Lo Presti, Saberio, et al.
Publicado: (2021)

COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies
por: Atri, Deepak, et al.
Publicado: (2020)

Incidence of myocarditis and pericarditis considered as separate clinical events over the years and post-SARS-CoV2 vaccination in adults and children
por: Conte, Edoardo, et al.
Publicado: (2023)

Role of genetic testing in cardiomyopathies: Α primer for cardiologists
por: Vogiatzi, Georgia, et al.
Publicado: (2022)

Mitochondrial Membrane Permeability Inhibitors in Acute Myocardial Infarction: Still Awaiting Translation
por: Trankle, Cory, et al.
Publicado: (2016)

Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial
por: Klein, Allan L, et al.
Publicado: (2021)

Fir(e)ing the Rhythm: Inflammatory Cytokines and Cardiac Arrhythmias
por: Lazzerini, Pietro Enea, et al.
Publicado: (2023)

COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
por: Ky, Bonnie, et al.
Publicado: (2020)

COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
por: Ky, Bonnie, et al.
Publicado: (2020)

Inflammasome Signaling, Thromboinflammation, and Venous Thromboembolism
por: Potere, Nicola, et al.
Publicado: (2023)

On the ethics of withholding and withdrawing medical treatment
por: Reichlin, Massimo
Publicado: (2014)

Disorders of neurogenesis and cortical development
por: Guarnieri, Fabrizia Claudia, et al.
Publicado: (2018)

Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease
por: Halpin, David M. G., et al.
Publicado: (2021)

Current evidence on the use of anti-RAAS agents in congenital or acquired solitary kidney
por: Simeoni, Mariadelina, et al.
Publicado: (2017)

Targeting inflammatory citokines to prevent constriction in tuberculous pericarditis and beyond?
por: Imazio, Massimo
Publicado: (2018)

Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept
por: Lin, David, et al.
Publicado: (2021)

Recurrent Pericarditis: a Stubborn Opponent Meets New Treatments in 2022
por: Hagerty, Tracy, et al.
Publicado: (2022)

CEACAM1 and MICA as novel serum biomarkers in patients with acute and recurrent pericarditis
por: Markel, Gal, et al.
Publicado: (2016)

Anti-SARS-CoV-2 vaccine-induced myocarditis – real but, in general, rare and mild: A consensus statement from the Studies Committee of the Portuguese Society of Cardiology
por: Sousa, José Pedro, et al.
Publicado: (2023)

New agents approved for treatment of acute staphylococcal skin infections
por: Tatarkiewicz, Jan, et al.
Publicado: (2016)

From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients
por: Eichler, H‐G, et al.
Publicado: (2015)

Recurrent Pericarditis in Children and Adolescents
por: Tombetti, Enrico, et al.
Publicado: (2019)

Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis
por: Wang, Tom Kai Ming, et al.
Publicado: (2022)

Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging
por: Di Giovanni, Giuseppe, et al.
Publicado: (2022)

Glucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial Ischemia
por: Giblett, Joel P., et al.
Publicado: (2016)

Emergent processes in cognitive-emotional interactions
por: Pessoa, Luiz
Publicado: (2010)

Bipolar disorder
por: Goodwin, Frederick K., et al.
Publicado: (1999)

Depression in late life
por: Barry, D. Lebowitz
Publicado: (1999)

The treatment of schizophrenia: from premorbid manifestations to the first episode of psychosis
por: Davidson, Michael, et al.
Publicado: (2005)

Genetic bases for endophenotypes in psychiatric disorders
por: Berrettini, Wade H.
Publicado: (2005)

The pharmacological management of depression
por: Kupfer, David J.
Publicado: (2005)

Sleep and psychiatry
por: Abad, Vivien C., et al.
Publicado: (2005)

Various forms of depression
por: Benazzi, Franco
Publicado: (2006)

Chronobiology and mood disorders
por: Wirz-Justice, Anna
Publicado: (2003)

Concepts in human biological rhythms
por: Reinberg, Alain, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_b7shdasmhav21ojuobmqhvu5sr